Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-08-08

Clinical Trial Update: Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating aflibercept for idiopathic choroidal neovascularization in young patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EYLEA (Aflibercept)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Idiopathic Choroidal Neovascularization | Phase 2 | Status: COMPLETED